SCI时时刷

search
+
Defects in intratumoral arginine metabolism attenuate the replication and therapeutic efficacy of oncolytic myxoma virus
WHAT IS ALREADY KNOWN ON THIS TOPICArginine (Arg) is known to be required for the replication of numerous oncolytic viruse...
Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8+ T cells
IntroductionInterleukin (IL)-2 was the first Food and Drug Administration approved immunotherapy for use in patients with ...
Optimal dosing regimen of CD73 blockade improves tumor response to radiotherapy through iCOS downregulation
WHAT IS ALREADY KNOWN ON THIS TOPICEven if the combination of irradiation and immmunotherapy can ameliorate the efficacy o...
Management of immune-related cutaneous adverse events with dupilumab
BackgroundImmune checkpoint inhibitors (ICI) have dramatically increased progression-free survival and overall survival in...
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
BackgroundIn recent years, the advent of immunotherapy has changed the treatment strategy for solid tumors.1 Several anti-...
CD71+ erythroid cells suppress T-cell effector functions and predict immunotherapy outcomes in patients with virus-associated solid tumors
WHAT IS ALREADY KNOWN ON THIS TOPICImmune checkpoint inhibitors (ICIs) have provided a novel avenue for cancer treatment, ...
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma
WHAT IS ALREADY KNOWN ON THIS TOPICWHAT THIS STUDY ADDSData from this first-in-human phase Ib trial show that the combinat...
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
IntroductionCell cycle kinases cyclin-dependent kinase (CDK) 4 and CDK 6 facilitate cell cycle progression through the G1 ...
Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors
IntroductionImmunotherapies (IT) and immune checkpoint inhibitors (ICI) opened a new era in cancer treatment. ICI unleash ...
Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies
IntroductionUnderstanding the role of the immune system in oncogenesis and tumor progression has led to the development of...
Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report
IntroductionCheckpoint inhibitor therapies have revolutionized the treatment of some solid tumors but have not proven to b...
Correction: Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy
Sharma S, Woods M, Mehta NU, et al. Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: i...
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
IntroductionT cells play a central role in cancer immunosurveillance and eradication.1 The generation of effective tumor-d...
Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia
IntroductionB-cell acute lymphoblastic leukemia (B-ALL) is an aggressive form of childhood and adult lymphoid malignancy.1...
The NR_109/FUBP1/c-Myc axis regulates TAM polarization and remodels the tumor microenvironment to promote cancer development
BackgroundContributing to tumorigenesis and tumor development, the tumor microenvironment (TME) contains a complex profile...
CAR T-cell detection scoping review: an essential biomarker in critical need of standardization
IntroductionThe advent of chimeric antigen receptor (CAR) T-cell therapies for treatment of hematological malignancies has...
Radiomic and clinical data integration using machine learning predict the efficacy of anti-PD-1 antibodies-based combinational treatment in advanced breast cancer: a multicentered study
IntroductionAmong malignancies, breast cancer has been a significant cause of tumor-related deaths around the world.1 Alth...
Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
BackgroundPatients with metastatic melanoma often respond well to checkpoint inhibitor treatment. The response rates incre...
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
WHAT IS ALREADY KNOWN ON THIS TOPICHOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICYBackgroundDue to its high tumor...
Combining histological grade, TILs, and the PD-1/PD-L1 pathway to identify immunogenic tumors and de-escalate radiotherapy in early breast cancer: a secondary analysis of a randomized clinical trial
BackgroundAdjuvant radiotherapy (RT) after breast-conserving surgery (BCS) significantly decreases the incidence of ipsila...
Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity
BackgroundBlocking immune checkpoints has transformed cancer treatment, demonstrating unprecedented responses in patients ...
Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial
IntroductionColorectal cancer (CRC) is the third most diagnosed cancer and accounts for the second most deaths due to canc...
Dual receptor T cells mediate effective antitumor immune responses via increased recognition of tumor antigens
Dual receptor T cells disproportionately contribute to effective immune rejection of tumorTo evaluate the role of dual TCR...
Correction: Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids
Meng Q, Xie S, Gray GK, et al. Empirical identification and validation of tumor-targeting T cell receptors from circulatio...
Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis
IntroductionImmunosuppressive tumor microenvironment (ITM) is generally identified to be the primary reason of many immuno...
Nasal administration of recombinant Neospora caninum secreting IL-15/IL-15R{alpha} inhibits metastatic melanoma development in lung
IntroductionMelanoma is the deadliest form of skin cancer worldwide, accounting for 3% of these cancers but 65% of their m...
OncoVEXmGM-CSFexpands tumor antigen-specific CD8+ T-cell response in preclinical models
WHAT IS ALREADY KNOWN ON THIS TOPICTalimogene laherparepvec (T-VEC) is a first-in-class modified herpes simplex virus type...
AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells
IntroductionCurrently ongoing clinical trials and approved drugs for cancer immunotherapy are mainly focused on monoclonal...
Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade
IntroductionThe last decade has demonstrated that immunotherapies can be robust and effective treatments for several previ...
Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression
IntroductionIn the last years, immunotherapy has emerged as a very promising treatment against cancer. Immune checkpoint i...
阅读更多
format_indent_increase